anaxirone has been researched along with Neoplasms in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hilgard, P; Peukert, M; Pohl, J | 1 |
Fiebig, HH; Heim, ME; Peukert, M; Possinger, K; Queisser, W; Wander, HE | 1 |
Crespeigne, N; Decoster, G; Dodion, P; Gerard, B; Kenis, Y; Lambert, M; Nicaise, C; Rozencweig, M | 1 |
Cunningham, D; Forrest, GJ; Gilchrist, NL; Kaye, SB; Setanoians, A; Soukop, M; Stuart, JF | 1 |
Bach, F; Cavalli, F; Hansen, HH; Hansen, SW; Kaplan, S | 1 |
5 other study(ies) available for anaxirone and Neoplasms
Article | Year |
---|---|
alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Kinetics; Metabolic Clearance Rate; Mice; Neoplasms; Neoplasms, Experimental; Rats; Triazines; Triazoles | 1984 |
Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer Society.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Prognosis; Triazoles | 1986 |
Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Triazoles | 1986 |
A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Triazoles | 1986 |
Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.
Topics: Adult; Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Phlebitis; Thrombocytopenia; Triazoles | 1985 |